SG/PUT/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 18:11:27 13/06/2024 BST | ||
| 2.66 EUR | +5.14% |
|
| 1 month | +15.15% | ||
| 3 months | +65.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 2.66 | +5.14% |
| 12/06/24 | 2.53 | +0.80% |
| 11/06/24 | 2.51 | -1.18% |
| 10/06/24 | 2.54 | -3.79% |
| 07/06/24 | 2.64 | -0.75% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 06:11 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ6K9V |
| ISIN | DE000SQ6K9V1 |
| Date issued | 20/12/2022 |
| Strike | 70 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.77 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | -0.07 € |
| Spread % | 2.71% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Warrants
- Warrant